Biotech News

aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting

aTyr Pharma (ATYR)aTyr PharmaCompany update

ATYR2810 substantially inhibits tumor growth and metastasis of osteosarcoma to the lungs, the main driver of poor outcomes, in preclinical studies. Anti-tumor benefits continued after treatment with ATYR2810 ended, without evidence of overt toxicity, supporting the potential of ATYR2810 in an

Related news

ATYRaTyr Pharma2026-10-13 12:00 EST

aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry

ATYRaTyr Pharma2026-10-19 11:00 EST

aTyr Pharma Announces Research Collaboration with Montefiore Einstein

BMYBMYBristol-Myers Squibb Company2026-11-06 21:00 EST

Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions

BMYBMYBristol-Myers Squibb Company2026-11-18 14:10 EST

Bristol Myers Squibb Presents First Clinical Data from Two Phase 3 Studies in the ADEPT Program Evaluating KarXT for Psychosis Associated with Alzheimer’s Disease

IMMPImmutep Limited2026-11-05 13:00 EST

Immutep Announces Upcoming Poster Presentations at CTOS 2026 and ESMO Immuno-Oncology & Advanced Therapies Congress 2026

TLSATiziana Life Sciences2026-10-21 11:00 EST

Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto

ELDNEledon Pharmaceuticals, Inc.2026-10-05 20:05 EST

Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting

SABSSAB Biotherapeutics2026-09-22 12:30 EST

SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes

ELDNEledon Pharmaceuticals, Inc.2026-09-22 11:00 EST

Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society

REGNRegeneron Pharmaceuticals2026-11-12 22:00 EST

POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms

aTyr Pharma

tRNA Synthetase Biology aTyr Pharma is a clinical-stage biotechnology company translating extracellular signaling functions of tRNA synthetases into therapies for fibrosis and inflammation. Its discovery platform searches domains derived from the 20 human tRNA synthetases for new therapeutic intervention points. Efzofitimod Efzofitimod...

Recent company news

Stock data

Close
3.69 USD
Market cap
50.99M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States